- All Courts
- Federal Courts
- Bankruptcies
- PTAB
- ITC
Filters
Like full text docket searches?
Get docket alerts, perform legal research, get updates of major decisions and orders, use our advanced analytics, and more. Request a Demo or create your account.
Date Filed
Dollars
Find cases based on dollar amount with searches like:
$100k-$10M.
Read the details here.
Displaying 114-128 of
195 results
1019 Exhibit: Griebel, et al
Document
PGR2022-00025, No. 1019-18 Exhibit - Griebel, et al (P.T.A.B. Feb. 18, 2022)
|
|
Cite Document
3001 Exhibit: Email
Document
PGR2022-00025, No. 3001 Exhibit - Email (P.T.A.B. Jul. 5, 2022)
|
|
Cite Document
2021 Exhibit: US Patent App No 18009,537 Filing Receipt
Document
PGR2022-00025, No. 2021 Exhibit - US Patent App No 18009,537 Filing Receipt (P.T.A.B. Aug. 12, 2024)
|
|
Cite Document
2025 Exhibit: US Patent App No 17311,310 Information Disclosure Statement date...
Document
PGR2022-00025, No. 2025 Exhibit - US Patent App No 17311,310 Information Disclosure Statement dated December 15, 2021 (P.T.A.B. Aug. 12, 2024)
|
|
Cite Document
2024 Exhibit: US Patent App No 17311,310 Filing Receipt
Document
PGR2022-00025, No. 2024 Exhibit - US Patent App No 17311,310 Filing Receipt (P.T.A.B. Aug. 12, 2024)
|
|
Cite Document
1033 Exhibit: Shargel Applied Biopharmaceutics Pharmacokinetics 7th ed 2016
Document
PGR2022-00025, No. 1033 Exhibit - Shargel Applied Biopharmaceutics Pharmacokinetics 7th ed 2016 (P.T.A.B. Feb. 18, 2022)
|
|
Cite Document
1013 Exhibit: Speiser Congenital Adrenal Hyperplasia Due to Steroid 21 Hydroxyla...
Document
PGR2022-00025, No. 1013 Exhibit - Speiser Congenital Adrenal Hyperplasia Due to Steroid 21 Hydroxylase Deficiency An Endocrine Society Clinical Practice Guideline (P.T.A.B. Feb. 18, 2022)
|
|
Cite Document
1008 Exhibit: Turcu Single Dose Study of a Corticotropin Releasing Factor Recepto...
Document
PGR2022-00025, No. 1008 Exhibit - Turcu Single Dose Study of a Corticotropin Releasing Factor Receptor 1 Antagonist in Women With 21 Hydroxylase Deficiency (P.T.A.B. Feb. 18, 2022)
|
|
Cite Document
1011 Exhibit: Spruce Biosciences Presents Phase 1 and 2 Data for Tildacerfont in A...
Document
PGR2022-00025, No. 1011 Exhibit - Spruce Biosciences Presents Phase 1 and 2 Data for Tildacerfont in Adults with Congenital Adrenal Hyperplasia from Endocrine Societys 2021 Annual Meetin...
|
|
Cite Document
1004 Exhibit: US Provisional Application Serial No 62545,406
Document
PGR2022-00025, No. 1004 Exhibit - US Provisional Application Serial No 62545,406 (P.T.A.B. Feb. 18, 2022)
|
|
Cite Document
1028 Exhibit: Neurocrine Biosciences Reports Positive Phase II Data for Crinecerfo...
Document
PGR2022-00025, No. 1028 Exhibit - Neurocrine Biosciences Reports Positive Phase II Data for Crinecerfont in Adults with Congenital Adrenal Hyperplasia at ENDO Online 2020 (P.T.A.B. Feb. 18...
|
|
Cite Document
1021 Exhibit: Merke New Ideas for Medical Treatment of Congenital Adrenal Hyper...
Document
PGR2022-00025, No. 1021 Exhibit - Merke New Ideas for Medical Treatment of Congenital Adrenal Hyperplasia (P.T.A.B. Feb. 18, 2022)
|
|
Cite Document
1002 Exhibit: US Prosecution History of the 201 Patent
Document
PGR2022-00025, No. 1002 Exhibit - US Prosecution History of the 201 Patent (P.T.A.B. Feb. 18, 2022)
|
|
Cite Document
1001 Exhibit: US Patent No 11,007,201 to Alexis Howerton, et al
Document
PGR2022-00025, No. 1001 Exhibit - US Patent No 11,007,201 to Alexis Howerton, et al (P.T.A.B. Feb. 18, 2022)
|
|
Cite Document
1016 Exhibit: Merke Congenital Adrenal Hyperplasia
Document
PGR2022-00025, No. 1016 Exhibit - Merke Congenital Adrenal Hyperplasia (P.T.A.B. Feb. 18, 2022)
|
|
Cite Document
